Disease relevance of [4-(2-dimethylamino-1-methyl-ethoxy)phenyl]-[2-(2-dimethylamino-1-methyl-ethoxy)-3-pyridyl]methanone

• Effects of a novel synthetic compound, Y-19995, on the host defence in immunocompromised mice were investigated in terms of the restoration of leukocytopenia and the protection against several microbial infections [1].
• The clearance of Escherichia coli from the blood of X-ray irradiated mice was also promoted by the treatment with Y-19995 [1].
• In addition, Y-19995 treatment could potentiate antibody-dependent cell-mediated cytotoxicity of polymorphonuclear leukocytes against the virus-infected target cells, and the production of serum neutralizing antibody to influenza virus in untreated and cyclophosphamide-treated mice [2].
• Intravenous administration of Y-19995 increased significantly the survival rates of X-ray irradiated mice against acute systemic infections with Escherichia coli, Pseudomonas aeruginosa and Candida albicans, and intramuscular infection with Escherichia coli [1].

High impact information on [4-(2-dimethylamino-1-methyl-ethoxy)phenyl]-[2-(2-dimethylamino-1-methyl-ethoxy)-3-pyridyl]methanone

• Furthermore, the treatment with Y-19995 augmented the inactivation of virus by the polymorphonuclear leukocytes [2].
• However, the virus inactivation by alveolar macrophages was modified only slightly by Y-19995 treatment [2].
• The augmented protection against microbial infections in immunocompromised hosts by Y-19995 may be attributed mainly to the prevention of leukocytopenia or the enhanced restoration from leukocytopenia [1].

Biological context of [4-(2-dimethylamino-1-methyl-ethoxy)phenyl]-[2-(2-dimethylamino-1-methyl-ethoxy)-3-pyridyl]methanone

• These results suggested that the activation of phagocytic cell functions by Y-19995 contributed to the enhancement of host defence in immunocompromised hosts [3].

References